{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:20:34Z","timestamp":1769912434175,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cytomegalovirus (CMV) infection remains a major complication after heart transplantation with varying prophylaxis strategies employed. We sought to determine the impact of valganciclovir (<jats:styled-content style=\"fixed-case\">VGC<\/jats:styled-content>) duration on the epidemiology of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infections after heart transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a prospective cohort study of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> donor (D) or recipient (R) seropositive heart transplant recipients from 2005 to 2012 who completed <jats:styled-content style=\"fixed-case\">VGC<\/jats:styled-content> prophylaxis, ranging from 3 to 12\u00a0months according to serostatus and induction immunosuppression. Univariate and multivariate logistic regression was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 159 heart transplant recipients during the study period, 130 (82%) were eligible for <jats:styled-content style=\"fixed-case\">VGC<\/jats:styled-content> prophylaxis. <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> D\/R serostatus was as follows: 24% D+\/R\u2212, 30% D+\/R+, and 29% D\u2212\/R+. 65% and 21% received basiliximab and thymoglobulin induction, respectively, followed by maintenance tacrolimus, mycophenolate mofetil, and prednisone. Twenty\u2010one (16%) recipients suffered <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection. There was no association with comorbidities including diabetes mellitus, chronic kidney disease, or mechanical assist devices, nor were there associations with rejection, treatments of rejection, or mortality. When <jats:styled-content style=\"fixed-case\">VGC<\/jats:styled-content> prophylaxis duration was stratified by \u22646 vs \u226512\u00a0months, time from heart transplantation to <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection was delayed (median 247 vs 452\u00a0days, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.002) but there was no difference in days from <jats:styled-content style=\"fixed-case\">VGC<\/jats:styled-content> discontinuation to onset of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection (median 72 vs 83\u00a0days, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.31). <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection occurred most frequently within 6\u201016\u00a0weeks of <jats:styled-content style=\"fixed-case\">VGC<\/jats:styled-content> cessation, and 95% of infections occurred during the 6\u00a0months post\u2010prophylaxis period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Relative to \u22646\u00a0months, \u226512\u00a0months of <jats:styled-content style=\"fixed-case\">VGC<\/jats:styled-content> did not reduce incidence of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection and only delayed time to onset. 95% of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection occurs within 6\u00a0months after cessation of <jats:styled-content style=\"fixed-case\">VGC<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12896","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T23:47:58Z","timestamp":1522453678000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cytomegalovirus infection in heart transplantation: A single center experience"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6301-0121","authenticated-orcid":false,"given":"Ignacio A.","family":"Echenique","sequence":"first","affiliation":[{"name":"Department of Infectious Disease Cleveland Clinic Florida  Weston FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Angarone","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Department of Medicine Northwestern University Feinberg School of Medicine  Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Rich","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Medicine Northwestern University Feinberg School of Medicine  Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Cardiology Department of Medicine Northwestern University Feinberg School of Medicine  Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Stosor","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Department of Medicine Northwestern University Feinberg School of Medicine  Chicago IL USA"},{"name":"Division of Organ Transplantation Department of Surgery Northwestern University Feinberg School of Medicine  Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"issue":"11","key":"e_1_2_8_2_1","first-page":"II207","article-title":"Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function","volume":"110","author":"Petrakopoulou P","year":"2004","journal-title":"Circulation"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.711911"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2004.03.009"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000229039.87735.76"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.05.007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420240075030"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90535-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.02.009"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318238dab3"},{"key":"e_1_2_8_11_1","first-page":"CD003774","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson EM","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2014.08.043"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.07.016"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2008.02.002"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03074.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008111166"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-12-201006150-00003"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.03.019"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.08.011"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12103"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12447"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1321-1"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.03.015"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2003.tb00255.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2011.00705.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12408"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1086\/322663"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21280"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2003.08.034"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12417"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001825"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12779"},{"key":"e_1_2_8_35_1","volume-title":"Defining Hispanicity: E Pluribus Unum or E Pluribus Plures?","author":"Tienda M","year":"2006"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2014.12.012"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.011676"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12896","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T15:52:40Z","timestamp":1694965960000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/tid.12896"],"URL":"https:\/\/doi.org\/10.1111\/tid.12896","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"2017-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12896"}}